GATC Health to Host Business Development Meetings in San Francisco during the Annual J.P. Morgan Healthcare Conference

January 8, 2026—GATC Health today announced that several of its executives will be in San Francisco next week during the annual J.P. Morgan Healthcare Conference to engage new biotech executives, investment leaders, and reporters around Derisq™, the Pre-Investment Report Predicting Safety, Efficacy and Off-Target Risk. 

GATC Health leadership will continue the launch of our groundbreaking AI, Derisq, which helps biopharma innovators and investors make faster, data‑driven decisions to streamline development pipelines and improve success rates across the industry.

“The JP Morgan Healthcare Conference represents an annual kickoff for the healthcare industry each January,” stated Tyrone Lam, Chief Business Officer of GATH Health. “We believe that it is very important for our team members to meet current and potential stakeholders face-to-face during this key event in San Francisco. Building awareness for our revolutionary technology and articulating its value proposition across the entire drug development value chain will be our main objectives for this event to drive future growth and adoption.”

Purpose of our JPM presence:

• Strengthen alignment with existing shareholders and partners by showcasing recent advances in GATC Health’s Operon™ AI platform and Derisq™ AI reports.
• Meet with institutional and strategic investors interested in portfolio‑level risk assessment and value creation using Derisq™ across existing and prospective assets.
• Engage biotech management teams on using Derisq™ to predict drug candidate safety, efficacy, and non‑obvious side effects prior to major capital deployment.  

How this supports our stakeholders:

• The Derisq™ AI report delivers a structured, decision‑ready risk profile for each drug candidate, helping reduce costly late‑stage failures and sharpen R&D and investment decisions—directly supporting value creation for shareholders and partners. 
• By positioning GATC Health as a go‑to partner for de‑risking pipelines and portfolios, these JPM‑week meetings are designed to expand commercial traction, unlock new collaboration opportunities, and accelerate adoption of our platform. 

GATC Health Team Attending:

• Jayson Uffens, Chief Technology Officer
• Ian Jenkins, Chief Science Officer
• Tyrone Lam, Chief Business Officer

About GATC Health
GATC Health is a tech-bio company revolutionizing drug discovery and development by simulating complex human biology to predict how drugs will perform in the body, achieving 91% specificity and 86% sensitivity. Trusted by the world’s largest insurance marketplace, biopharma, researchers, and investment partners, GATC Health’s risk prediction product, the Derisq™ AI report, accurately assesses and predicts drug candidate safety, efficacy, and non-obvious side effects prior to the commitment of development capital. GATC Health’s AI platform is also generative, creating intellectual property, extending pipelines, and optimizing assets. By uniting advanced AI, multiomics, and predictive modeling, GATC Health accelerates breakthroughs and reduces costly late-stage failures to bring safer, more effective therapies to patients worldwide. For more information, visit www.gatchealth.com.